<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Clinical practice considerations. In: Laboratory medicine practice guidelines: guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ruaño G, Linder MW. Clinical practice considerations. In: Valdes R Jr, Payne DA, Linder MW, editor(s). Laboratory medicine practice guidelines: guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Washington (DC): National Academy of Clinical Biochemistry (NACB); 2010. p. 23-8. [43 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Acute venous embolism and thrombosis of unspecified deep vessels of lower extremity  (453.40); Attention deficit disorder with hyperactivity  (314.01); Attention deficit disorder with hyperactivity  (314.9); Poisoning by unspecified drug or medicinal substance  (977.9); Rheumatoid arthritis  (714.0); Venous embolism and thrombosis of superficial vessels of lower extremity  (453.6)"/><FieldValue Value="MSH: Arthritis, Rheumatoid ; Attention Deficit Disorder with Hyperactivity ; Azathioprine ; Camptothecin ; Clinical Laboratory Techniques ; Cytochrome P-450 CYP2C9 ; Cytochrome P-450 CYP2D6 ; Drug Therapy ; Genetic Techniques ; Genetic Testing ; Genetic Variation ; HLA-B Antigens ; Individualized Medicine ; Methyltransferases ; Mixed Function Oxygenases ; Mutation ; Neoplasms ; Patient-Centered Care ; Pharmacogenetics ; Propylamines ; Quality Assurance, Health Care ; Quality Control ; Reproducibility of Results ; Sensitivity and Specificity ; Tamoxifen ; Venous Thrombosis ; Warfarin "/><FieldValue Value="MTH: abacavir ; Attention deficit hyperactivity disorder ; Azathioprine ; CYP2C19 protein, human ; CYP2C9 gene ; Cytochrome P-450 CYP2D6 ; Cytochrome p450 CYP2C9 enzyme ; Drug toxicity ; Genetic screening method ; HLA-B Antigens ; Methyltransferase ; Mixed Function Oxygenases ; Mutation ; Neoplasms ; Pharmacogenetics ; Pharmacogenomics ; Pharmacotherapy ; quality control ; Rheumatoid Arthritis ; Tamoxifen ; Thiopurine S-Methyltransferase ; UGT1A1 gene ; Variation (Genetics) ; Venous Thrombosis ; Warfarin "/><FieldValue Value="PDQ: camptothecin ; CYP2C9 ; drug toxicity ; UGT1A1 ; warfarin "/><FieldValue Value="SNOMEDCT_US: Abacavir  (116084008); Abacavir  (387005008); Atomoxetine  (407037005); Atomoxetine  (407038000); Attention deficit hyperactivity disorder  (406506008); Attention deficit hyperactivity disorder  (7461003); Azathioprine  (111165009); Azathioprine  (372574004); Camptothecin  (95994003); Cytochrome p450 CYP2C9 enzyme  (422602005); Cytochrome p450 CYP2D6 enzyme  (425292000); Drug therapy  (416608005); Extensive metabolizer due to cytochrome p450 CYP2D6 variant  (422510002); Genetic mutation  (55446002); Genetic test  (405824009); Genetic variation  (64195000); HLA-B antigen  (54481006); Irinotecan  (108783005); Irinotecan  (372538008); Methyltransferase  (130055001); Mixed function oxygenase  (129923001); Mixed function oxygenase  (423265008); Molecular genetic test  (405825005); Neoplasm  (108369006); Poisoning by drug AND/OR medicinal substance  (7895008); Poor metabolizer due to cytochrome p450 CYP2C19 variant  (424500005); Poor metabolizer due to cytochrome p450 CYP2C9 variant  (424451001); Poor metabolizer due to cytochrome p450 CYP2D6 variant  (423629005); Propylamine  (259273007); Rheumatoid arthritis  (69896004); Tamoxifen  (373345002); Tamoxifen  (75959001); Thiopurine methyltransferase  (6896003); Ultrarapid metabolizer due to cytochrome p450 CYP2D6 variant  (422681000); Venous thrombosis  (111293003); Warfarin  (372756006); Warfarin  (48603004)"/><FieldValue Value="UMD: Analyzers, Laboratory, Molecular Assay, Genetic Testing  (20-803); Molecular Microarrays, Mutation/Polymorphism, Gene CYP2D6/CYP2C19  (20-820)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Diseases or conditions for which analysis of gene variations may be used for purposes of guiding the use of medications and related therapeutics&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Assessment of Therapeutic Effectiveness" /><FieldValue Value="Diagnosis" /><FieldValue Value="Technology Assessment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Hematology" /><FieldValue Value="Infectious Diseases" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Medical Genetics" /><FieldValue Value="Oncology" /><FieldValue Value="Pathology" /><FieldValue Value="Pharmacology" /><FieldValue Value="Psychiatry" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Clinical Laboratory Personnel" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Hospitals" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Public Health Departments" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To establish practice guidelines for application of pharmacogenetics (PGx) in the practice of laboratory medicine &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide evidence based recommendations for establishing guidelines and set future criteria for clinical implementation of pharmacogenetics to the bedside &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Individuals with genetic variants associated with drug-metabolizing enzyme&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical use of the most current variant alleles for &lt;em&gt;CYP2D6&lt;/em&gt;, &lt;em&gt;CYP2C9&lt;/em&gt;, and &lt;em&gt;CYP2C19&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Thiopurine methyltransferase&lt;/em&gt; (&lt;em&gt;TPMT&lt;/em&gt;) enzyme genotyping (azathioprine model) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;CYP2C9&lt;/em&gt; and &lt;em&gt;VKOR C1&lt;/em&gt; genotyping (warfarin model) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;CYP2D6&lt;/em&gt; genotyping (tamoxifen model) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;CYP2D6&lt;/em&gt; genotyping (atomoxetine model) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;UGT1A1&lt;/em&gt; genotyping for high-intensity irinotecan (Camptosar) regimen &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genotyping for human lymphocyte &lt;em&gt;HLA-B*5701&lt;/em&gt; prior to administering abacavir &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical predictive value of testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Allele variant frequency &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;For a specific clinical use, pertinent clinical questions were formulated and key search terms were ascertained for the literature search. A time frame of literature searches was conducted from 1995 until December 2009 on MEDLINE or PubMed databases. The specific search terms were pharmacogenetics, pharmacogenomics, clinical applications of pharmacogenetics, personalized medicine and clinical laboratories.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evidence includes consistent results from well-designed, well-conducted studies in representative populations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to routine practice; or indirect nature of the evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information. Expert consensus is the basis for the recommendation. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt;. The National Academy of Clinical Biochemistry (NACB) strongly recommends adoption; there is good evidence that it improves important health outcomes and concludes that benefits substantially outweigh harms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt;. The NACB recommends adoption; there is at least fair evidence that it improves important health outcomes and concludes that benefits outweigh harms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt;. The NACB recommends against adoption; there is evidence that it is ineffective or that harm outweighs benefit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt;. The NACB concludes that the evidence is insufficient to make recommendations; evidence that it is effective is lacking, of poor quality, or conflicting; and the balance of benefits and harms cannot be determined.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This document was approved by the National Academy of Clinical Biochemistry (NACB) Board of Directors in July 2009. The NACB is the Academy of the American Association for Clinical Chemistry.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions of the levels of evidence (&lt;strong&gt;I&amp;mdash;III&lt;/strong&gt;) and the strength of recommendations (&lt;strong&gt;A, B, C, I&lt;/strong&gt;) are presented at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;&lt;strong&gt;Note from the National Academy of Clinical Biochemistry (NACB) and the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice&lt;/em&gt; has been divided into individual summaries. In addition to the current summary, the following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=15659&quot; title=&quot;Guideline #7695&quot;&gt;Methodology and quality assurance considerations in pharmacogenetic testing&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=15662&quot; title=&quot;Guideline #7698&quot;&gt;Clinical laboratory services considerations&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=15663&quot; title=&quot;Guideline #7699&quot;&gt;Reporting and interpretation of pharmacogenetic test results&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=15665&quot; title=&quot;Guideline #7701&quot;&gt;Therapeutic drug monitoring and pharmacogenetics interface considerations&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=15666&quot; title=&quot;Guideline #7702&quot;&gt;Ancillary applications: drug prescription/dispensing and forensics&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=15667&quot; title=&quot;Guideline #7703&quot;&gt;Regulatory considerations&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Which are the most current variant alleles for &lt;em&gt;CYP2D6&lt;/em&gt;, &lt;em&gt;CYP2C9&lt;/em&gt;, and &lt;em&gt;CYP2C19&lt;/em&gt; recommended for clinical use?&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation 1&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The following variant alleles are recommended when performing pharmacogenetic (PGx) genotyping for &lt;em&gt;CYP2D6&lt;/em&gt;, &lt;em&gt;CYP2C9&lt;/em&gt;, and &lt;em&gt;CYP2C19&lt;/em&gt; &lt;strong&gt;(B-III)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;What set of criteria (characteristics) should be required of a PGx test to make it useful in a clinical laboratory setting?&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation 2&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;For a PGx test to be useful in a clinical laboratory setting, it is recommended that the test have analytical and operational features that render them useful and compatible with clinical practice &lt;strong&gt;(B-II)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;What examples are available that can presently be used&amp;nbsp;as models for application of PGx testing in clinical settings?&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Azathioprine Model&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation 3&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Thiopurine methyltransferase (TPMT)&lt;/em&gt; genotyping is recommended as a useful adjunct to a regimen for prescribing azathioprine &lt;strong&gt;(A-I)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Warfarin Model&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation 4&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;A combination of &lt;em&gt;CYP2C9&lt;/em&gt; and &lt;em&gt;VKOR C1&lt;/em&gt; genotyping are the recommended PGx tests as adjuncts to individually adjusted dosages for warfarin therapy &lt;strong&gt;(A-II)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Tamoxifen (Nolvadex) Model&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation 5&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;CYP2D6&lt;/em&gt; genotyping may be useful as an adjunct to a regimen for prescribing tamoxifen &lt;strong&gt;(B-III)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Atomoxetine (Strattera) Model&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation 6&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;CYP2D6&lt;/em&gt; genotyping may be useful as an adjunct to a regimen for prescribing atomoxetine (Strattera) &lt;strong&gt;(B-III)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Irinotecan (Camptosar) Model&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation 7&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;UGT1A1&lt;/em&gt; genotyping is recommended as a useful adjunct for high-intensity irinotecan (Camptosar) dosing regimens &lt;strong&gt;(A-II)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Abacavir Model&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation 8&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Genotyping for human lymphocyte &lt;em&gt;HLA-B*5701&lt;/em&gt; is recommended prior to administering abacavir for patients who are infected with the human immunodeficiency virus (HIV), in order to avoid the development of a delayed hypersensitivity reaction &lt;strong&gt;(A-II)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evidence includes consistent results from well-designed, well-conducted studies in representative populations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to routine practice; or indirect nature of the evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information. Expert consensus is the basis for the recommendation. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt;. The National Academy of Clinical Biochemistry (NACB) strongly recommends adoption; there is good evidence that it improves important health outcomes and concludes that benefits substantially outweigh harms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt;. The NACB recommends adoption; there is at least fair evidence that it improves important health outcomes and concludes that benefits outweigh harms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt;. The NACB recommends against adoption; there is evidence that it is ineffective or that harm outweighs benefit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt;. The NACB concludes that the evidence is insufficient to make recommendations; evidence that it is effective is lacking, of poor quality, or conflicting; and the balance of benefits and harms cannot be determined.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see &quot;Major Recommendations&quot;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Establishing appropriate criteria for the clinical application of pharmacogenetics&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ruaño G, Linder MW. Clinical practice considerations. In: Valdes R Jr, Payne DA, Linder MW, editor(s). Laboratory medicine practice guidelines: guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Washington (DC): National Academy of Clinical Biochemistry (NACB); 2010. p. 23-8. [43 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="National Academy of Clinical Biochemistry - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;National Academy of Clinical Biochemistry&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;National Academy of Clinical Biochemistry (NACB) Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Committee Members&lt;/em&gt;: Roland Valdes Jr, PhD, DABCC, FACB, University of Louisville, Louisville, KY; Deborah A. Payne, PhD, DABMM, DABCC, FACB, Molecular Services, UniPath LLC, Denver, CO; Mark W. Linder, PhD, DABCC, FACB, Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY; Gilbert Burckhart, PhD, Pharmacy, University of Southern California, Los Angeles, CA; Daniel H. Farkas, PhD, HCLD, Sequenom Center for Molecular Medicine, Grand Rapids, MI; Felix Frueh, PhD, Medco Health Solutions Inc, Bethesda, MD; Jean-Pierre Morello, PhD, Teva Neuroscience Canada, Montreal, Quebec, Canada; Atiqur Rahman, PhD, Division of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD; Gualberto Rua&amp;ntilde;o, MD, PhD, Genomas Inc and Hartford Hospital, Hartford CT; Les Shaw, PhD, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; Saeed Jortani, PhD, DABCC, FACB, Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY; Werner Steimer, MD, Department of Clinical Chemistry and Pathobiochemistry, Institut fur Klinische Chemie und Pathobiochemie, Munich, Germany; Steven Wong, PhD, Department of Pathology, Medical College of Wisconsin, Milwaukee, WI; Jeanne Carr, PhD, Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/LAACP/Documents/PGx_Guidelines.pdf&quot; title=&quot;NACB Web site&quot;&gt;National Academy of Clinical Biochemistry (NACB) Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: National Academy of Clinical Biochemistry publications are available through American Association for Clinical Chemistry (AACC) Press. To make a purchase or request a catalog, contact AACC Customer Service at 202-857-0717 or &lt;a href=&quot;mailto:custserv@aacc.org&quot;&gt;custserv@aacc.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on November 3, 2010. The information was verified by the guideline developer on December 15, 2010.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;National Academy of Clinical Biochemistry's (NACB) terms for reproduction of guidelines are posted with each set of guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
